Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
Employees - 14,
CEO - Mr. James B. Frakes M.B.A.,
Sector - Healthcare,
Country - US,
Market Cap - 10.84M
Altman ZScore(max is 10): -27.18, Piotroski Score(max is 10): 1, Working Capital: $4806633, Total Assets: $8847330, Retained Earnings: $-159945141, EBIT: -11365664, Total Liabilities: $2828222, Revenue: $0
- Current Price $0.58 - Analyst Target Price $3.85| Ticker | AEMD |
| Index | - |
| Curent Price | 0.58 |
| Change | 33.83% |
| Market Cap | 10.84M |
| Average Volume | 2.35M |
| Income | -11.27M |
| Sales | 0.00M |
| Book Value/Share | 0.43 |
| Cash/Share | 0.37 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 14 |
| Moving Avg 20days | 41.57% |
| Moving Avg 50days | 45.33% |
| Moving Avg 200days | -14.80% |
| Shares Outstanding | 13.96M |
| Earnings Date | Nov 13 AMC |
| Inst. Ownership | 2.90% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | 1.35 |
| Price/Cash | 1.58 |
| Price/FCF | - |
| Quick Ratio | 3.06 |
| Current Ratio | 3.06 |
| Debt/Equity | 0.13 |
| Return on Assets | -103.99% |
| Return on Equity | -137.96% |
| Return on Investment | -172.96% |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 62.10 |
| BETA(β) | 1.80 |
| From 52week Low | 144.21% |
| From 52week High | -75.32% |
| EPS | -2.85 |
| EPS next Year | -0.69 |
| EPS next Qtr | -0.20 |
| EPS this Year | 80.04% |
| EPS next 5 Year | - |
| EPS past 5 Year | 37.58% |
| Sales past 5 Year | 24.87% |
| EPS Y/Y | 41.76% |
| Sales Y/Y | -100.00% |
| EPS Q/Q | 83.52% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | -2.56% |
| ATR(14) | 0.10 |
| Perf Week | 61.74% |
| Perf Month | 48.76% |
| Perf Quarter | 38.10% |
| Perf Year | -69.15% |
| Perf YTD | -73.52% |
| Target Price | 3.85 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer